Valuation: HeraMED Limited

Market Cap 55.61M 39.17M 34.38M 32.31M 29.54M 55.2M 3.75B 388M 150M 1.91B 147M 144M 6.2B P/E 2024
-1.94x
P/E 2025 -9.23x
Enterprise Value 54.24M 38.2M 33.53M 31.52M 28.81M 53.84M 3.66B 379M 147M 1.87B 143M 140M 6.05B EV / Sales 2024
39.6x
EV / Sales 2025 86.1x
Free-Float
69.25%
Yield 2024 *
-
Yield 2025 -

Last Transcript: HeraMED Limited

1 day-4.17%
1 week+12.20%
Current month+27.78%
1 month+21.05%
3 months+39.39%
6 months+17.95%
Current year+27.78%
1 week 0.04
Extreme 0.041
0.05
1 month 0.03
Extreme 0.033
0.05
Current year 0.03
Extreme 0.03
0.06
1 year 0.03
Extreme 0.03
0.06
3 years 0.01
Extreme 0.006
0.07
5 years 0.01
Extreme 0.006
0.34
10 years 0.01
Extreme 0.006
0.34
Manager TitleAgeSince
Chief Executive Officer - 2024-04-08
Director of Finance/CFO - 2024-04-08
Chief Operating Officer - 2022-09-30
Director TitleAgeSince
Director/Board Member 62 2018-08-20
Director/Board Member - 2024-05-09
Chairman - 2024-05-09
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%+12.20%+6.98%-34.29% 37.06M
-0.61%-3.99%-26.80%-4.16% 106B
-2.23%-3.31%-25.26%-2.99% 11.57B
-3.98%-6.11%+81.24%+103.89% 9.42B
+0.13%+5.21%-48.06%-66.10% 4.2B
+2.83%+7.86%-20.43%+30.25% 2.45B
-3.14%-5.07%-10.36%-62.67% 2.06B
+1.25%+10.10% - - 1.98B
+0.77%+2.25%-18.76%-26.45% 1.54B
Average -1.02%+4.72%-7.68%-7.81% 15.42B
Weighted average by Cap. -0.89%-3.34%-19.42%+0.95%

Financials

2024 2025
Net sales 364K 257K 225K 212K 194K 362K 24.58M 2.54M 986K 12.53M 963K 942K 40.63M 432K 304K 267K 251K 229K 428K 29.12M 3.01M 1.17M 14.84M 1.14M 1.12M 48.13M
Net income -5.49M -3.87M -3.39M -3.19M -2.92M -5.45M -370M -38.32M -14.85M -189M -14.52M -14.2M -612M -4.13M -2.91M -2.55M -2.4M -2.19M -4.1M -279M -28.83M -11.18M -142M -10.93M -10.69M -461M
Net Debt -3.08M -2.17M -1.91M -1.79M -1.64M -3.06M -208M -21.52M -8.34M -106M -8.16M -7.98M -344M -1.37M -965K -847K -796K -728K -1.36M -92.46M -9.57M -3.71M -47.14M -3.62M -3.55M -153M
Logo HeraMED Limited
HeraMED Limited is an Australia-based medical data and technology company. The Company is engaged in the digital transformation of maternity care by transforming the prenatal and postpartum experience with its hybrid maternity care platform. The Company offers a proprietary platform that utilizes hardware and software to reshape the doctor/patient relationship using its clinically validated in-home fetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data. The HeraBEAT medical device is used by pregnant women in Europe, the United States, Israel and Australia. The Company’s proprietary offering, HeraCARE, is engineered to offer a fully integrated maternal health ecosystem designed to deliver care to ensure expectant mothers are engaged, informed and well-supported, allowing healthcare professionals to provide quality care and enable early detection and prevention of potential risks.
Employees
-
Date Price Change Volume
26-09-23 A$0.0460 -4.17% 1,157,735
26-09-23 A$0.0480 +6.67% 1,198,695
26-09-22 A$0.0450 +9.76% 1,141,506
26-09-21 A$0.0410 -2.38% 2,369,577
26-09-18 A$0.0420 +2.44% 1,303,533